138 related articles for article (PubMed ID: 10466627)
21. ZFN-mediated in vivo gene editing in hepatocytes leads to supraphysiologic α-Gal A activity and effective substrate reduction in Fabry mice.
Pagant S; Huston MW; Moreira L; Gan L; St Martin S; Sproul S; Holmes MC; Meyer K; Wechsler T; Desnick RJ; Yasuda M
Mol Ther; 2021 Nov; 29(11):3230-3242. PubMed ID: 33775910
[TBL] [Abstract][Full Text] [Related]
22. Lentivector transduction improves outcomes over transplantation of human HSCs alone in NOD/SCID/Fabry mice.
Pacienza N; Yoshimitsu M; Mizue N; Au BC; Wang JC; Fan X; Takenaka T; Medin JA
Mol Ther; 2012 Jul; 20(7):1454-61. PubMed ID: 22472949
[TBL] [Abstract][Full Text] [Related]
23. Long-term expression of human argininosuccinate synthetase in mice following bone marrow transplantation with retrovirus-transduced hematopoietic stem cells.
Demarquoy J; Herman GE; Lorenzo I; Trentin J; Beaudet AL; O'Brien WE
Hum Gene Ther; 1992 Feb; 3(1):3-10. PubMed ID: 1562637
[TBL] [Abstract][Full Text] [Related]
24. Non-viral, integrin-mediated gene transfer into fibroblasts from patients with lysosomal storage diseases.
Estruch EJ; Hart SL; Kinnon C; Winchester BG
J Gene Med; 2001; 3(5):488-97. PubMed ID: 11601762
[TBL] [Abstract][Full Text] [Related]
25. Transplantation of retrovirus-transduced canine keratinocytes expressing the beta-galactosidase gene.
Stockschläder MA; Schuening FG; Graham TC; Storb R
Gene Ther; 1994 Sep; 1(5):317-22. PubMed ID: 7584097
[TBL] [Abstract][Full Text] [Related]
26. Sequencing and characterization of the porcine α-galactosidase A gene: towards the generation of a porcine model for Fabry disease.
Yoshimitsu M; Higuchi K; Fan X; Takao S; Medin JA; Tei C; Takenaka T
Mol Biol Rep; 2011 Jun; 38(5):3145-52. PubMed ID: 20131008
[TBL] [Abstract][Full Text] [Related]
27. Characterization of Fabry mice treated with recombinant adeno-associated virus 2/8-mediated gene transfer.
Choi JO; Lee MH; Park HY; Jung SC
J Biomed Sci; 2010 Apr; 17(1):26. PubMed ID: 20398385
[TBL] [Abstract][Full Text] [Related]
28. Multiple reduced-intensity conditioning regimens facilitate correction of Fabry mice after transplantation of transduced cells.
Liang SB; Yoshimitsu M; Poeppl A; Rasaiah VI; Cai J; Fowler DH; Medin JA
Mol Ther; 2007 Mar; 15(3):618-27. PubMed ID: 17228315
[TBL] [Abstract][Full Text] [Related]
29. Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adeno-associated virus-mediated gene transfer.
Park J; Murray GJ; Limaye A; Quirk JM; Gelderman MP; Brady RO; Qasba P
Proc Natl Acad Sci U S A; 2003 Mar; 100(6):3450-4. PubMed ID: 12624185
[TBL] [Abstract][Full Text] [Related]
30. Promoter-specific lentivectors for long-term, cardiac-directed therapy of Fabry disease.
Lee CJ; Fan X; Guo X; Medin JA
J Cardiol; 2011 Jan; 57(1):115-22. PubMed ID: 20846825
[TBL] [Abstract][Full Text] [Related]
31. Alpha-galactosidase A-Tat fusion enhances storage reduction in hearts and kidneys of Fabry mice.
Higuchi K; Yoshimitsu M; Fan X; Guo X; Rasaiah VI; Yen J; Tei C; Takenaka T; Medin JA
Mol Med; 2010; 16(5-6):216-21. PubMed ID: 20454522
[TBL] [Abstract][Full Text] [Related]
32. Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele.
Yasuda M; Shabbeer J; Benson SD; Maire I; Burnett RM; Desnick RJ
Hum Mutat; 2003 Dec; 22(6):486-92. PubMed ID: 14635108
[TBL] [Abstract][Full Text] [Related]
33. High overexpression of the human alpha-galactosidase A gene driven by its promoter in transgenic mice: implications for the treatment of Fabry disease.
Ashley GA; Desnick RJ; Gordon RE; Gordon JW
J Investig Med; 2002 May; 50(3):185-92. PubMed ID: 12033283
[TBL] [Abstract][Full Text] [Related]
34. Correction of cardiac abnormalities in fabry mice by direct intraventricular injection of a recombinant lentiviral vector that engineers expression of alpha-galactosidase A.
Yoshimitsu M; Higuchi K; Dawood F; Rasaiah VI; Ayach B; Chen M; Liu P; Medin JA
Circ J; 2006 Nov; 70(11):1503-8. PubMed ID: 17062978
[TBL] [Abstract][Full Text] [Related]
35. Lentivirus-mediated gene therapy for Fabry disease.
Khan A; Barber DL; Huang J; Rupar CA; Rip JW; Auray-Blais C; Boutin M; O'Hoski P; Gargulak K; McKillop WM; Fraser G; Wasim S; LeMoine K; Jelinski S; Chaudhry A; Prokopishyn N; Morel CF; Couban S; Duggan PR; Fowler DH; Keating A; West ML; Foley R; Medin JA
Nat Commun; 2021 Feb; 12(1):1178. PubMed ID: 33633114
[TBL] [Abstract][Full Text] [Related]
36. Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates.
Zhu X; Yin L; Theisen M; Zhuo J; Siddiqui S; Levy B; Presnyak V; Frassetto A; Milton J; Salerno T; Benenato KE; Milano J; Lynn A; Sabnis S; Burke K; Besin G; Lukacs CM; Guey LT; Finn PF; Martini PGV
Am J Hum Genet; 2019 Apr; 104(4):625-637. PubMed ID: 30879639
[TBL] [Abstract][Full Text] [Related]
37. lacZ transgenic rats tolerant for beta-galactosidase: recipients for gene transfer studies using lacZ as a reporter gene.
Ménoret S; Aubert D; Tesson L; Braudeau C; Pichard V; Ferry N; Anegon I
Hum Gene Ther; 2002 Jul; 13(11):1383-90. PubMed ID: 12162820
[TBL] [Abstract][Full Text] [Related]
38. Use of recombinant adeno-associated viral vectors as a tool for labeling bone marrow cells.
Iwakura A; Dean J; Hamada H; Eaton E; Qin G; Losordo DW; Aikawa R
J Mol Cell Cardiol; 2005 May; 38(5):799-802. PubMed ID: 15850573
[TBL] [Abstract][Full Text] [Related]
39. Naked plasmid DNA-based alpha-galactosidase A gene transfer partially reduces systemic accumulation of globotriaosylceramide in Fabry mice.
Nakamura G; Maruyama H; Ishii S; Shimotori M; Kameda S; Kono T; Miyazaki J; Kulkarni AB; Gejyo F
Mol Biotechnol; 2008 Feb; 38(2):109-19. PubMed ID: 18219591
[TBL] [Abstract][Full Text] [Related]
40. Myeloproliferative sarcoma virus directed expression of beta-galactosidase following retroviral transduction of murine hematopoietic cells.
Clapp DW; Freie B; Srour E; Yoder MC; Fortney K; Gerson SL
Exp Hematol; 1995 Jul; 23(7):630-8. PubMed ID: 7601255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
